David Malcom Rodman Sells 7,709 Shares of Mineralys Therapeutics (NASDAQ:MLYS) Stock

Mineralys Therapeutics, Inc. (NASDAQ:MLYS) insider David Malcom Rodman sold 7,709 shares of Mineralys Therapeutics stock in a transaction dated Tuesday, January 13th. The stock was sold at an average price of $32.75, for a total transaction of $252,469.75. Following the transaction, the insider directly owned 61,804 shares in the company, valued at $2,024,081. This trade represents a 11.09% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link.

David Malcom Rodman also recently made the following trade(s):

• On Wednesday, January 14th, David Malcom Rodman sold 11,367 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.61, for a total transaction of $370,677.87.
• On Monday, January 12th, David Malcom Rodman sold 6,348 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $32.32, for a total transaction of $205,167.36.
• On Friday, January 9th, David Malcom Rodman sold 2,170 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $33.27, for a total value of $72,195.90.
• On Friday, January 2nd, David Malcom Rodman sold 70,037 shares of Mineralys Therapeutics stock. The stock was sold at an average price of $35.87, for a total value of $2,512,227.19.
• On Monday, January 5th, David Malcom Rodman sold 192,715 shares of Mineralys Therapeutics stock. The shares were sold at an average price of $35.02, for a total value of $6,748,879.30.

Mineralys Therapeutics Stock Up 4.3%

Shares of Mineralys Therapeutics stock opened at $32.74 on Friday. The firm has a market cap of $2.59 billion, a PE ratio of -11.10 and a beta of 0.49. Mineralys Therapeutics, Inc. has a 52 week low of $8.24 and a 52 week high of $47.65. The business’s fifty day simple moving average is $38.40 and its 200-day simple moving average is $31.04.

Mineralys Therapeutics (NASDAQ:MLYS) last issued its quarterly earnings data on Monday, November 10th. The company reported ($0.52) earnings per share (EPS) for the quarter, beating the consensus estimate of ($0.66) by $0.14. As a group, equities analysts expect that Mineralys Therapeutics, Inc. will post -4.23 earnings per share for the current year.

Analyst Upgrades and Downgrades

Several research firms recently weighed in on MLYS. HC Wainwright lifted their target price on shares of Mineralys Therapeutics from $52.00 to $56.00 and gave the company a “buy” rating in a report on Wednesday, November 12th. Stifel Nicolaus lifted their price objective on Mineralys Therapeutics from $45.00 to $52.00 and gave the company a “buy” rating in a research note on Friday, December 19th. Weiss Ratings reiterated a “sell (d-)” rating on shares of Mineralys Therapeutics in a report on Wednesday, October 8th. Finally, Wells Fargo & Company raised their target price on Mineralys Therapeutics from $50.00 to $55.00 and gave the company an “overweight” rating in a report on Tuesday, November 11th. Six equities research analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. Based on data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $47.43.

Institutional Trading of Mineralys Therapeutics

Several hedge funds have recently modified their holdings of the stock. Farallon Capital Management LLC purchased a new position in Mineralys Therapeutics in the third quarter valued at $63,442,000. Holocene Advisors LP acquired a new stake in Mineralys Therapeutics in the 3rd quarter valued at about $45,708,000. RA Capital Management L.P. boosted its stake in shares of Mineralys Therapeutics by 19.1% in the 3rd quarter. RA Capital Management L.P. now owns 7,323,750 shares of the company’s stock valued at $277,717,000 after buying an additional 1,176,470 shares during the period. Polar Capital Holdings Plc acquired a new position in shares of Mineralys Therapeutics during the third quarter worth about $40,149,000. Finally, Alliancebernstein L.P. increased its stake in shares of Mineralys Therapeutics by 3,160.1% during the third quarter. Alliancebernstein L.P. now owns 882,415 shares of the company’s stock worth $33,461,000 after buying an additional 855,348 shares during the period. 84.46% of the stock is currently owned by institutional investors and hedge funds.

Mineralys Therapeutics Company Profile

Mineralys Therapeutics, Inc, a clinical-stage biopharmaceutical company that develops therapies for the treatment of hypertension and chronic kidney diseases. It clinical-stage product candidate is lorundrostat, a proprietary, orally administered, highly selective aldosterone synthase inhibitor for the treatment of cardiorenal conditions affected by abnormally elevated aldosterone. The company was formerly known as Catalys SC1, Inc and changed its name to Mineralys Therapeutics, Inc in May 2020. The company was incorporated in 2019 and is headquartered in Radnor, Pennsylvania.